About Insulet
Insulet is a company based in Boston (United States) founded in 2000. Insulet has raised $120.4 million across 8 funding rounds from investors including TIAA, Orbimed and FirstMark. The company has 3,900 employees as of December 31, 2024. Insulet offers products and services including Omnipod. Insulet operates in a competitive market with competitors including Tandem Diabetes, Xeris Pharmaceuticals, Lyra Therapeutics, Valeritas and Credence MedSystems, among others.
- Headquarter Boston, United States
- Employees 3900 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Insulet Corporation
-
Annual Revenue
$2.07 B (USD)22.07as on Dec 31, 2024
-
Net Profit
$418.3 M (USD)102.76as on Dec 31, 2024
-
EBITDA
$389.7 M (USD)33.09as on Dec 31, 2024
-
Total Equity Funding
$120.4 M (USD)
in 8 rounds
-
Latest Funding Round
$201 M (USD), Post-IPO
Jun 03, 2014
-
Investors
TIAA
& 12 more
-
Employee Count
3900
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Insulet
Insulet is a publicly listed company on the NASDAQ with ticker symbol PODD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Insulet
Insulet offers a comprehensive portfolio of products and services, including Omnipod.
Tubeless wearable device for continuous insulin delivery to diabetes patients.
People of Insulet
Unlock access to complete
Unlock access to complete
Software Development Team
264 people
Senior Team
111 people
Product Management Team
78 people
Leadership Team
65 people
Sales and Marketing
56 people
Operations Team
23 people
Human Resources and Administration
20 people
Data Analysis and Operations Team
20 people
Unlock access to complete
Funding Insights of Insulet
Insulet has successfully raised a total of $120.4M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $201 million completed in June 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Insulet
Insulet has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include TIAA, Orbimed and FirstMark.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on healthcare companies
|
Locked | Locked | Locked |
Investor details for Insulet
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Insulet
Investment portfolio details for Insulet
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Insulet
Detailed financials for Insulet
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Insulet Comparisons
Peer comparison for Insulet
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Insulet
Insulet operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tandem Diabetes, Xeris Pharmaceuticals, Lyra Therapeutics, Valeritas and Credence MedSystems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of devices for continuous glucose monitoring and manual insulin delivery
|
|
| Locked | Locked | Locked |
Liquid-stable injectables are developed for peptide and protein drug delivery.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for ENT diseases are developed.
|
|
| Locked | Locked | Locked |
Wearable insulin patch pumps are developed for transdermal delivery.
|
|
| Locked | Locked | Locked |
Developer of smart devices for drug delivery
|
Detailed competitors of Insulet
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Insulet
Complete news archive for Insulet
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Insulet
Insulet was founded in 2000.
Insulet is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Duane DeSisto is the current CEO of Insulet.
Insulet is a funded company, having raised a total of $120.4M across 8 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Insulet is 3,900.
Annual revenue of Insulet is $2.07B as on Dec 31, 2024.
Insulet was founded in 2000 and is headquartered in Boston, United States. Operations focus on the medical device sector, where insulin infusion systems for insulin-dependent diabetes are developed, manufactured, and marketed. A key product includes a disposable infusion device with automated cannula insertion, paired with a handheld wireless diabetes manager. This setup supports diabetes management through integrated monitoring and delivery features.
Insulet's top competitors include Tandem Diabetes, Lyra Therapeutics and Xeris Pharmaceuticals.
Insulet offers Omnipod.
Yes, Insulet is publicly traded on NASDAQ under the ticker symbol PODD.
Insulet has 13 investors. Key investors include TIAA, Orbimed, FirstMark, Piper Jaffray, and Deerfield.
The ticker symbol of Insulet is PODD on NASDAQ.